|
|
|
xi | |
| Section I Background and early development |
|
1 | (54) |
|
The discovery of sumatriptan and a new class of drug for the acute treatment of migraine |
|
|
3 | (8) |
|
|
|
|
|
|
5-HT receptors in brain and vasculature |
|
|
11 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Structural and operational diversity of serotonin receptors: potential relevance to migraine pathophysiology and treatment |
|
|
23 | (12) |
|
|
|
|
|
|
Characterisation of 5-HT1 receptor expression in human vasculature |
|
|
35 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5-HT1B and 5-HT1D receptor immunoreactivity co-localizes with sensory neurotransmitters in the human trigeminal ganglion |
|
|
41 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upregulation of 5-HT1B/1D receptors during organ culture of cerebral arteries |
|
|
46 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Background and early development: discussion summary |
|
|
51 | (4) |
|
|
|
|
|
| Section II Pharmacology of the triptans |
|
55 | (68) |
|
Clinical pharmacokinetics of the triptans: what are the important clinical issues? |
|
|
57 | (15) |
|
|
|
|
|
|
Pharmacodynamics of triptans |
|
|
72 | (8) |
|
|
|
|
|
|
Characteristics of different routes of administration |
|
|
80 | (11) |
|
|
|
|
|
|
Encapsulation of sumatriptan does not delay its absorption |
|
|
91 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synergism of 5-HT1 and 5-HT2 receptors in sumatriptan-induced vasocontractile response in rabbit common carotid artery |
|
|
97 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Role of 5-HT1B and 5-HT1D receptors in sumatriptan-mediated vasocontractile response in rabbit common carotid artery |
|
|
103 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Comparison of triptan-induced contractions in human cerebral versus coronary arteries |
|
|
109 | (5) |
|
|
|
|
|
|
|
|
|
|
|
Pharmacological analysis of the contractile effects of eletriptan and sumatriptan on human isolated blood vessels |
|
|
114 | (6) |
|
|
|
|
|
|
Antoinette Maassen vandenbrink |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacology of the triptans: discussion summary |
|
|
120 | (3) |
|
|
|
|
|
| Section III Antimigraine actions of the triptans |
|
123 | (58) |
|
The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans |
|
|
125 | (9) |
|
|
|
|
|
|
|
|
|
|
|
Inhibition of neurogenic inflammation is most important |
|
|
134 | (8) |
|
|
|
|
|
|
Central nervous system effects are most important |
|
|
142 | (10) |
|
|
|
|
|
|
Do we really understand how the triptans work? |
|
|
152 | (6) |
|
|
|
|
|
|
The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT1B/1D agonists (triptans) in the treatment of migraine |
|
|
158 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In vivo serotonergic effects and extracellular brain levels of centrally and systemically administered eletriptan, zolmitriptan, and sumatriptan |
|
|
164 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regulation of capsaicin-evoked CGRP release from rat dural sensory neurons in vitro |
|
|
169 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arterial distensibility in ergotamine and sumatriptan abuse |
|
|
173 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antimigraine actions of the triptans: discussion summary |
|
|
178 | (3) |
|
|
|
|
|
| Section IV Clinical efficacy and tolerability of the triptans |
|
181 | (102) |
|
Sumatriptan: looking back and looking forward |
|
|
183 | (7) |
|
|
|
|
|
|
Zolmitriptan offers doctor and patient choices for effective treatment of migraine |
|
|
190 | (9) |
|
|
|
|
|
|
Rizatriptan: clinical update |
|
|
199 | (7) |
|
|
|
|
|
|
Evidence against fight correlation between chest oppressive symptoms and ischaemic coronary changes after subcutaneous sumatriptan injection |
|
|
206 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alteration in cluster headache during subcutaneous administration of sumatriptan |
|
|
211 | (4) |
|
|
|
|
|
|
Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes |
|
|
215 | (7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan |
|
|
222 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Naratriptan: the gentle triptan |
|
|
228 | (8) |
|
|
|
|
|
|
Experience with eletriptan (Relpax™) |
|
|
236 | (11) |
|
|
|
|
|
|
|
|
247 | (6) |
|
|
|
|
|
|
Frovatriptan---simplifying clinical practice in migraine |
|
|
253 | (9) |
|
|
|
|
|
|
Cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack |
|
|
262 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lack of clinically significant interactions between frovatriptan and ergotamine, propranolol, or moclobemide |
|
|
268 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frovatriptan pharmacokinetics are unaffected during a migraine attack |
|
|
274 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical efficacy and tolerability of the triptans: discussion summary |
|
|
279 | (4) |
|
|
|
|
|
| Section V The triptans in clinical practice |
|
283 | (54) |
|
Acute management of migraine: clinical trials of triptans versus other agents |
|
|
285 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Which triptan for which patient? |
|
|
297 | (8) |
|
|
|
|
|
|
The Framing 99 survey III: therapeutical behaviour of migraineurs |
|
|
305 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Migraine in France in 2000: therapeutical data |
|
|
309 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The triptan threshold score: a score to help patients identify the best moment to take the triptan |
|
|
314 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Triptan plus NSAID with a long half-life: increase of efficacy and reduction of headache recurrence in acute migraine |
|
|
318 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparison of the triptans with other drugs in the development of drug-induced headache |
|
|
323 | (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
An epidemiological study on the differences between sumatriptan and ergotamine overuse |
|
|
326 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Overuse of new 5-HT agonists (zolmitriptan and naratriptan) in migraine patients: clinical features |
|
|
331 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The triptans in clinical practice: discussion summary |
|
|
335 | (2) |
|
|
|
|
|
| Index |
|
337 | |
Other versions by this Author
